Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease

Ocular Immunology and Inflammation

Volumn 18, Issue 3, 2010, Pages 200-207

  Cuchacovich, Miguel ^a   Solanes, Federica ^a   Díaz, Gonzalo ^a   Cermenati, Tomás ^a   Avila, Samuel ^a   Verdaguer, Juan ^b   Verdaguer, Juan Ignacio ^c   Carpentier, Cristian ^c   Stopel, Juan ^c   Rojas, Basilio ^c   Traipe, Leonidas ^c   Gallardo, Patricia ^a   Sabugo, Francisca ^a   Zanoli, Mario ^c   Merino, Guillermo ^d   Villarroel, Francisco ^c  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD DE LOS ANDES   (Chile)

^d Luis Pasteur Ophthalmologic Institute   (Chile)

Author keywords

Azathioprine; Cyclosporine; Immunosupresive treatment; Uveitis; Vogt Koyanagi Harada

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; BORDERLINE HYPERTENSION; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HYPERTRICHOSIS; INFECTION; KIDNEY INJURY; LEUKOPENIA; LUNG INFECTION; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

ADOLESCENT; ADULT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY; YOUNG ADULT;

EID: 77952835987     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273941003587541     Document Type: Article

References (28)

1. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265-292.
2. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol. 2005;20:183-190.
3. Kotake S, Furudate N, Sasamoto Y, Yoshikawa K, Goda C, Matsuda H. Characteristics of endogenous uveitis in Hokkaido, Japan. Graefes Arch Clin Exp Ophthalmol. 1997;235:5-9.
4. Hirokuni Kitamei, Nobuyoshi Kitaichi, Kenichi Namba, et al. Clinical features of intraocular inflammation in Hokkaido, Japan. Acta Ophthalmol. 2009:87:424-428.
5. Ohno S, Char DH, Kimura SJ, O'Connor GR. Vogt-Koyanagi- Harada syndrome. Am J Ophthalmol. 1977;83:735-740.
6. Islam SMM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:752-756.
7. Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007;15:381-387.
8. Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm. 2008;16:161-165.
9. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69-75.
10. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
11. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30:287-290.
12. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234-235.
13. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Am J Ophthalmol. 1985;92:467-471.
14. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516.
15. Nussenblatt RB. Clinical studies of Vogt-Koyanagi-Harada's disease at the National Eye Institute, NIH, USA. Jpn J Ophthalmol. 1988;32:330-333.
16. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69-75.
17. Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi- Harada's disease. Jpn J Ophthalmol. 1988;32:334-343.
18. Cifuentes L, Morales, Sepulveda D, Jorquera H, Acuna M. DYS19 and DYS199 loci in a Chilean population of mixed ancestry. Am J Phys Anthropol. 2004; 125:85-89.
19. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1 0410. Br J Ophthalmol. 1994;78:223-226.
20. Goldberg AC, Yamamoto JH, Chiarella JM, et al. HLADRB1* 0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease. Hum Immunol. 1998;59:183-188.
21. Massardo L, Jacobelli S, Rodriguez L, Rivero S, Gonzalez A, Marchetti R. Weak association between HLA-DR4 and rheumatoid arthritis in Chilean patients. Ann Rheum Dis. 1990;49:290-292.
22. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998;105:2028-2034.
23. Read RW, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;142:119-124.
24. Vitale AT, Rodriguez A, Foster CS. Low dose cyclosporine A therapy in treating chronic, noninfectious uveitis. Ophthalomology. 1996;103:365-374.
25. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87-90.
26. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS.Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.Ophthalmology. 2003;110:1061-1065.
27. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682-687.
28. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008;16:167-171.